
Like all businesses in Canada, the Canadian Cardiovascular Society (CCS) is carefully assessing the impact of potential incoming tariffs on Canadian products by the United States, with particular focus on the implications for access to cardiovascular healthcare and medical supplies. Along with doing what we can to mitigate adverse impacts of tariffs on patients and cardiovascular professionals, we will adjust our business practices as needed to prioritize Canadian interests.
In this unsettling time, we will continue working with our partners, healthcare professionals, and policymakers to ensure uninterrupted access to the resources and innovations necessary to support heart health across the country. A 30-day delay in potential tariffs is only prolonging the uncertainty, and we remain steadfast in our commitment to Team Canada.
As a leading not-for-profit in the Canadian healthcare sector, the CCS will always advocate for policies that protect and enhance patient care, research, and medical advancements in Canadian cardiovascular health. We will provide further updates as more information becomes available.